Preventing HIV in Uganda: Increasing Access to Pre-exposure Prophylaxis (PrEP) Among People Who Inject Drugs

A new grant will help deliver HIV prevention services to people in Uganda who are injecting drugs.

Renee Heffron and Andrew Mujugira are key personnel on the grant, which will support research through 2025. The project will implement pre-exposure prophylaxis (PrEP), train a mental health staff, and also include project implementation, data collection, stakeholder engagement, and dissemination of the results to communities.

New Research Aimed at Promoting Better Patient Adherence to HIV Medications

Paul Drain—an Associate Professor in the Department of Global Health, Medicine and Epidemiology at the University of Washington—and his research team have received a new grant from the CoMotion Innovation Gap Fund, a program intended to help bridge the gap between academic research grants and the level of development needed to obtain investment. Drain’s project is titled “Rapid test for measuring adherence to antiretroviral therapy and pre-exposure prophylaxis”.  

PrEParing family planning clinics in Kenya to prevent new HIV infections

In sub-Saharan Africa, many young women and adolescent girls are at high risk of HIV infection. In a new research paper published in the open access journal PLOS Medicine, Kenneth Mugwanya and co-authors report on a study aiming to investigate the feasibility of providing antiretroviral drugs via family planning clinics to prevent HIV infection in young women.

PrEP Use High but Wanes after Three Months Among Young African Women

In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months. However, PrEP use fell among participants in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored, evidence-based adherence support strategies may be needed to durably engage young African women in consistent PrEP use. 

UW HIV Prevention Research Highlighted at International Conference

UW Department of Global Health researchers presented new HIV prevention findings at the HIV Research for Prevention (HIVR4P 2018) conference in Madrid. HIVR4P is the only global scientific conference focused exclusively on the challenging and fast-growing field of biomedical HIV prevention research.  The conference supports global cross-fertilization among research on HIV vaccines, microbicides, PrEP, treatment as prevention, and other biomedical prevention approaches.

The Lancet: Profile of Jared Baeten, Aiming to See Off HIV

By Tony Kirby

"The last person that I train, I want that training to be in something other than HIV", says Jared Baeten. Speaking to The Lancet Infectious Diseases from the HIV Research for Prevention Conference (HIVR4P) in Chicago, IL, where he brought a 12-strong team of his researchers, Baeten explains: “When that time comes, I want HIV to have been eliminated as public health threat, so we can focus on other diseases”. 

NewsBeat: Antiretrovirals Pose Low Risk to Nursing Mothers, Babies

Study involves researchers with UW International Clinical Research Center

By Bobbi Nodell

Researchers have found that breastfeeding mothers taking the antiretroviral drugs tenofovir and emtricitabine have a low risk of side effects. The study, published in PLOS, was conducted by colleagues at the UW International Clinical Research Center and partners in Kenya, Uganda and Johns Hopkins University.

Family Practice News: Oral HIV PrEP Also Protects Against Herpes

By Bruce Jancin

DURBAN, SOUTH AFRICA – Oral antiretroviral pre-exposure prophylaxis (PrEP) against HIV also reduces the risk of acquiring herpes simplex virus type 2, according to research presented at the 21st International AIDS Conference.

“Given the limited interventions for primary prevention of HSV-2, efficacy against HSV-2 provides additional benefit to oral PrEP,” observed Connie Celum, MD, professor of global health and medicine at the University of Washington, Seattle.

Pages